NewsBenzinga60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027 60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027 Benzinga 2026.10.06 12:19 (GMT+0) Open on Benzinga Other news Lockheed Martin's $88 Billion Missile Backlog Could Be a Reason to Buy Before October 22 Replit is no longer working with Anthropic, CEO says If You Invested $1000 In Watts Water Technologies Stock 15 Years Ago, You Would Have This Much Today 12 Consumer Discretionary Stocks Moving In Friday's After-Market Session 12 Health Care Stocks Moving In Friday's After-Market Session 12 Industrials Stocks Moving In Friday's After-Market Session
